Literature DB >> 7479958

Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation.

R S McDowell1, K A Elias, M S Stanley, D J Burdick, J P Burnier, K S Chan, W J Fairbrother, R G Hammonds, G S Ingle, N E Jacobsen, D L Mortensen, T E Rawson, W B Won, R G Clark, T C Somers.   

Abstract

Another class of growth hormone (GH) secretagogues has been discovered by altering the backbone structure of a flexible linear GH-releasing peptide (GHRP). In vitro and in vivo characterization confirms these GH secretagogues as the most potent and smallest (M(r) < 500) reported. Anabolic efficacy is demonstrated in rodents with intermittent delivery. A convergent model of the bioactive conformation of GHRPs is developed and is supported by the NMR structure of a highly potent cyclic analog of GHRP-2. The model and functional data provide a logical framework for the further design of low-molecular weight secretagogues and illustrate the utility of an interdisciplinary approach to elucidating potential bound-state conformations of flexible peptide ligands.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479958      PMCID: PMC40592          DOI: 10.1073/pnas.92.24.11165

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  13 in total

1.  Design, synthesis, and biological activity of peptides which release growth hormone in vitro.

Authors:  F A Momany; C Y Bowers; G A Reynolds; D Chang; A Hong; K Newlander
Journal:  Endocrinology       Date:  1981-01       Impact factor: 4.736

2.  Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites.

Authors:  A D Blake; R G Smith
Journal:  J Endocrinol       Date:  1991-04       Impact factor: 4.286

3.  Pseudo-structures for the 20 common amino acids for use in studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear magnetic resonance.

Authors:  K Wüthrich; M Billeter; W Braun
Journal:  J Mol Biol       Date:  1983-10-05       Impact factor: 5.469

4.  On the actions of the growth hormone-releasing hexapeptide, GHRP.

Authors:  C Y Bowers; A O Sartor; G A Reynolds; T M Badger
Journal:  Endocrinology       Date:  1991-04       Impact factor: 4.736

5.  The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture.

Authors:  K Cheng; W W Chan; A Barreto; E M Convey; R G Smith
Journal:  Endocrinology       Date:  1989-06       Impact factor: 4.736

6.  Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides.

Authors:  F A Momany; C Y Bowers; G A Reynolds; A Hong; K Newlander
Journal:  Endocrinology       Date:  1984-05       Impact factor: 4.736

7.  On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.

Authors:  C Y Bowers; F A Momany; G A Reynolds; A Hong
Journal:  Endocrinology       Date:  1984-05       Impact factor: 4.736

8.  Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors.

Authors:  M I Goth; C E Lyons; B J Canny; M O Thorner
Journal:  Endocrinology       Date:  1992-02       Impact factor: 4.736

9.  GH releasing peptides--structure and kinetics.

Authors:  C Y Bowers
Journal:  J Pediatr Endocrinol       Date:  1993 Jan-Mar

10.  Variables determining the growth hormone response of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the rat.

Authors:  O Sartor; C Y Bowers; G A Reynolds; F A Momany
Journal:  Endocrinology       Date:  1985-10       Impact factor: 4.736

View more
  5 in total

1.  Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue.

Authors:  L C Pan; P A Carpino; B A Lefker; J A Ragan; S M Toler; J C Pettersen; D O Nettleton; O Ng; C M Pirie; K Chidsey-Frink; B Lu; D F Nickerson; D A Tess; M A Mullins; D B MacLean; P A DaSilva-Jardine; D D Thompson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

2.  An integrated method to determine epithelial transport and bioactivity of oral drug candidates in vitro.

Authors:  W Rubas; M E Cromwell; R J Mrsny; G Ingle; K A Elias
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

3.  Synthesis, stability and mechanistic studies of potent anticryptococcal hexapeptides.

Authors:  Kitika Shenmar; Krishna K Sharma; Nishima Wangoo; Indresh K Maurya; Vinod Kumar; Shabana I Khan; Melissa R Jacob; Kulbhushan Tikoo; Rahul Jain
Journal:  Eur J Med Chem       Date:  2017-03-24       Impact factor: 6.514

4.  Growth hormone-releasing hormone (GHRH) polymorphisms associated with carcass traits of meat in Korean cattle.

Authors:  Hyun Sub Cheong; Du-Hak Yoon; Lyoung Hyo Kim; Byung Lae Park; Yoo Hyun Choi; Eui Ryong Chung; Yong Min Cho; Eng Woo Park; Il-Cheong Cheong; Sung-Jong Oh; Sung-Gon Yi; Taesung Park; Hyoung Doo Shin
Journal:  BMC Genet       Date:  2006-06-03       Impact factor: 2.797

5.  Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats.

Authors:  Junghun Lee; Ahreum Kwon; Hyun Wook Chae; Woo Jung Lee; Tae Hyuk Kim; Ho Seong Kim
Journal:  Yonsei Med J       Date:  2018-12       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.